Recent Updates
Recently added Catalysts

REGENXBIO Inc.

RGNXFDA catalysts, PDUFA dates & pipeline intelligence
$7.24
▼ -0.08 · -1.09%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full RGNX financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $5.4652W HIGH $16.19
Volume
963.09 K
Value Traded
6.88 M
Short % Float
16.64%
Days to Cover
8.3
-14.52%Week
+1.26%1 Month
-39.77%3 Month
+21.27%6 Month
-82.29%5 Year
-79.02%All Time

Cash Data

Unlock RGNX cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
478.73 M
EPS (TTM)
-2.65
P/E Ratio
-
Ent. Value
227.75 M
Total Shares
66.12 M
Float Shares
61.16 M
Insiders
7.51%
Institutions
70.75%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
BLA Submission
RGX-202
Duchenne muscular dystrophy
Fast TrackOrphanRare Pediatric
BLAGene TherapiesNeurology
Unlock every RGNX catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

RGNX Catalyst Timeline

Dated clinical, regulatory and corporate events for REGENXBIO Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for REGENXBIO Inc.

1072Total events
22Upcoming
219Tier-1 (high impact)
2015 to 2027Coverage

Upcoming catalysts 2

T1Topline Readout
Subscribe to view catalyst details
surabogene lomparvovec
T1NDA Submission
Subscribe to view catalyst details
RGX-202

Event history 50

●Quarterly UpdateCorporate
Reported third quarter 2026 financial results and operational highlights
▲Legal / SettlementCorporate
Settlement agreement with Sarepta Therapeutics resolving all patent litigation; $39.0 million payment received
▲Long Term Datasurabgene lomparvovecClinical Data
Positive three-year durability data from Phase II ALTITUDE in NPDR (Dose Level 3)
non-proliferative diabetic retinopathysource ↗
▲Oral Presentationsurabgene lomparvovecPresentation
Three-year ALTITUDE data presented at Retina Society Annual Scientific Meeting
diabetic retinopathysource ↗
▲Long Term Datasurabgene lomparvovecClinical Data
Long-term follow-up data from ALTITUDE through 3 years presented at Retina Society 59th Annual Scientific Meeting
diabetic retinopathysource ↗
●Management ChangeCorporate
Greg Ciongoli appointed to Board of Directors
▼Clinical Hold PlacedRGX-121FiledIND
FDA placed clinical hold on RGX-121 following spine MRI findings
▼Clinical Hold PlacedRGX-111IND
Clinical hold related to RGX-111
▲Long Term Datasurabgene lomparvovecClinical Data
Positive three-year durability data from Phase II ALTITUDE in NPDR
non-proliferative diabetic retinopathysource ↗
●Quarterly UpdateCorporate
Reported Q2 2026 financial results
Unlock the full RGNX catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How RGNX actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-09-30NAVSUNLI (clemidsogene lanparvovec-sngl, RGX-121) BLA Submission BLA
Unlock 8 more RGNX historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 12%
Micro Cap
(rank 88 of 725)
Percentile Rank
Showing 4 of 5 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
RGX-202 Gene TherapiesNCT05693142Duchenne Muscular DystrophyPhase 2/3 ACTIVE NOT_RECRUITING 65Jun 1, 2028
RGX-121 Gene TherapiesNCT03566043Mucopolysaccharidosis Type II (MPS II)Phase 2/3 ACTIVE NOT_RECRUITING 54Aug 1, 2025
RGX-121 Gene TherapiesNCT07236606MPS IINDA/BLA ACTIVE NOT_RECRUITING 2May 30, 2031
RGX-314 Gene TherapiesCompletedNCT03066258Neovascular Age-related Macular DegenerationPhase 1/2 COMPLETED 42Jun 17, 2021
Unlock the RGNX pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every RGNX program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
surabgene lomparvovec wet AMD and diabetic retinopathyPhase 1/2a2026-07-18Stable to improved vision through 5 years in wet AMD patients; No drug-related intraocular inflammation observed; >2-step DRSS improvement in majority of NPDR participants at 2.5 yearsRead MoreREGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual MeetingRead More
Scroll for more · summaries link to the source press release
Unlock every RGNX trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock RGNX insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Ciongoli Gregory AustinDirectorBuy 53,407 118,035 held$9.36 08/27/2026
Unlock the full RGNX insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
Redmile Group, LLC 2.8 % (-20 %) 38.02 M 5.05 M 15.56% ( 679.70 K)
Unlock every fund holding RGNX
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in RGNX
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see RGNX ownership
Insider and institutional ownership, quarter by quarter.

RGNX Short Interest

Shares sold short, counted twice a month.

16.64%
Short % of Float
of tradable shares sold short
10.2M
Shares Sold Short
+1.4% vs prior count
8.3 High
Days to Cover
trading days of normal volume to buy every short share back
1.2M
Avg Daily Volume
the average used for days to cover
Unlock RGNX short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock RGNX option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live RGNX option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock RGNX options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How RGNX ranks across every disease it competes in

Competitive Position is a premium feature
See how RGNX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

RGNX News

RGNX
Nov 5, 2026
RGNXGeneral

REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights

REGENXBIO reported its Q3 2026 financial results, highlighting progress in its gene therapy pipeline. The company is on track to submit a BLA for RGX-202 in Q1 2027 and expects pivotal data for sura-vec in Q4 2026. Despite a clinical hold on RGX-121, REGENXBIO maintains a strong cash position of $251 million.

Read more →
RGNX
Nov 3, 2026
RGNXConferences/Events
▲ +6.6%on this newsshared move

REGENXBIO to Participate in Stifel 2026 Healthcare Conference

REGENXBIO Inc. will participate in the Stifel 2026 Healthcare Conference on November 11, 2026. The event will feature a fireside chat at 9:20 a.m. ET in New York. A live webcast will be available on the company's website, with an archived replay for 30 days.

Read more →
RGNX
Oct 29, 2026
RGNXConferences/Events

REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights

REGENXBIO Inc. will hold a conference call on November 5 to discuss its third quarter financial results and operational highlights. The call is scheduled for 8:00 a.m. ET, and listeners can register online. The company is known for its advancements in gene therapy, particularly in treating rare and retinal diseases.

Read more →
RGNX
Oct 12, 2026
RGNXConferences/Events

REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20

REGENXBIO Inc. will host an investor event on October 20, 2026, to discuss the clinical program for surabgene lomparvovec (sura-vec) in wet AMD. The event will feature insights from leading retina specialists and is set to precede the anticipated topline pivotal data readout in Q4 2026. The event will be held in New York and available via webcast.

Read more →
RGNX
Sep 24, 2026
RGNXPhases

REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting

REGENXBIO presented positive three-year data for surabgene lomparvovec at the Retina Society Annual Scientific Meeting. The Phase II ALTITUDE study showed that 60% of participants with non-proliferative diabetic retinopathy achieved significant improvement without additional treatment. No safety concerns were reported, reinforcing the therapy's potential as a transformative one-time treatment.

Read more →
RGNX
Sep 8, 2026
RGNXConferences/Events

REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO Inc. will participate in two upcoming investor conferences in New York on September 15 and 16, 2026. The company aims to showcase its advancements in gene therapy, particularly its late-stage pipeline targeting rare and retinal diseases. Live webcasts of the events will be available on their website.

Read more →
RGNX
Aug 25, 2026
RGNXGeneral
▲ +10.6%on this news

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli

REGENXBIO Inc. has appointed Greg Ciongoli to its Board of Directors as the company prepares for its next phase of growth. Ciongoli brings extensive experience in biotechnology investing and corporate strategy. Concurrently, long-serving board members Jerry Karabelas and Jean Bennett are retiring. The company aims to leverage Ciongoli's expertise to advance its late-stage gene therapy pipeline.

Read more →
RGNX
Aug 24, 2026
RGNXFDA Updates
▼ -24.9%on this newsshared move

REGENXBIO Announces Regulatory Update on RGX-121 for MPS II

REGENXBIO has announced a clinical hold on its gene therapy RGX-121 for MPS II after asymptomatic spine MRI findings were reported in five study participants. The company does not anticipate resubmitting the Biologics License Application soon. Despite the hold, participants remain clinically stable, and REGENXBIO is focusing on other therapies in its pipeline.

Read more →
RGNX
Aug 6, 2026
RGNXGeneral
▲ +7.4%on this news

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

REGENXBIO reported strong financial results and operational highlights for Q2 2026, with a focus on advancing its gene therapy pipeline. Key developments include the initiation of the RGX-202 BLA submission for Duchenne muscular dystrophy and positive data from ongoing trials for RGX-121 and surabgene lomparvovec. The company raised over $200 million to support its operations and extend its cash runway into Q4 2027.

Read more →
RGNX
Aug 3, 2026
RGNXConferences/Events

REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights

REGENXBIO Inc. will host a conference call on August 6, 2026, at 8:00 a.m. ET to discuss its second quarter financial results and operational highlights. The call will include a question and answer session for analysts. A replay will be available shortly after the call concludes.

Read more →
RGNX
Jul 18, 2026
RGNXPhases

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

REGENXBIO presented positive long-term data for surabgene lomparvovec (sura-vec) at the ASRS Annual Meeting. The gene therapy demonstrated stable to improved vision in wet AMD patients over five years, with no drug-related intraocular inflammation. Additionally, it showed significant improvements in diabetic retinopathy patients at 2.5 years. Topline data from pivotal studies are expected in Q4 2026.

Read more →
RGNX
Jul 17, 2026
RGNXGeneral
▼ -11.7%on this newsshared move

REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants

REGENXBIO Inc. has announced the pricing of a public offering of over 10 million shares of common stock at $9.00 each, along with pre-funded warrants. The offering is expected to raise around $100 million and is set to close on July 20, 2026. The company has granted underwriters a 30-day option to purchase additional shares.

Read more →
RGNX
Jul 16, 2026
RGNXGeneral
▼ -11.7%on this newsshared move

REGENXBIO Announces Proposed Public Offering of Common Stock

REGENXBIO Inc. has announced a proposed public offering of $100 million in common stock, subject to market conditions. The company plans to grant underwriters a 30-day option to purchase additional shares. This offering is part of their strategy to support their gene therapy pipeline, which includes treatments for various diseases.

Read more →
RGNX
Jun 29, 2026
RGNXPhases
▲ +12.9%on this news· ran to +27% by day 3

REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone

REGENXBIO has announced the dosing of the first patient in its Phase IIb/III NAAVIGATE trial for surabgene lomparvovec, a gene therapy for diabetic retinopathy. The company will receive a $100 million milestone payment from AbbVie. This trial aims to evaluate the safety and efficacy of sura-vec, which has shown promising results in previous studies.

Read more →
RGNX
Jun 24, 2026
RGNXFDA Updates

REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026

REGENXBIO has successfully completed dosing in the confirmatory study of RGX-202, a gene therapy for Duchenne muscular dystrophy, ahead of schedule. This positions the company to submit a Biologics License Application (BLA) in Q3 2026, aiming for FDA approval by late 2027. The study demonstrated strong efficacy and safety, aligning with accelerated approval criteria.

Read more →
RGNX
Jun 22, 2026
RGNXFDA Updates
▲ +16.3%on this news· ran to +31% by day 3shared move

REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II

REGENXBIO has aligned with the FDA on the next steps for the accelerated approval of NAVSUNLI, a gene therapy for MPS II. The FDA confirmed that no additional studies are needed and will review existing data on an expedited basis. The company plans to resubmit the Biologics License Application in Q3 2026 after a Type A meeting with the FDA.

Read more →
RGNX
May 14, 2026
RGNXPhases
▼ -37.8%on this newsshared move

REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights

REGENXBIO Inc. reported positive topline results from its pivotal Phase III AFFINITY DUCHENNE study of RGX-202, achieving its primary endpoint with high statistical significance. The results demonstrated a significant correlation between microdystrophin expression and functional improvement in patients. Additionally, the clinical hold on RGX-121 has been lifted, indicating progress in developing treatments for Hunter syndrome. Financial results showed a substantial net loss for the first quarter of 2026, reflecting challenges in revenue generation amidst ongoing operational efforts.

Read more →
RGNX
May 14, 2026
RGNXPhases
▼ -37.8%on this newsshared move

REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202

REGENXBIO has announced positive topline results from the Phase III AFFINITY DUCHENNE trial for RGX-202, showing that 93% of participants achieved significant microdystrophin expression. The data also indicate a strong correlation between this expression and functional improvement over a year. The therapy is reported to have a favorable safety profile, with no serious long-term adverse effects documented. As a result of these findings, REGENXBIO is preparing for potential accelerated approval in 2027.

Read more →
RGNX
May 7, 2026
RGNXConferences/Events

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

REGENXBIO Inc. announced its participation in the 2026 American Society of Gene & Cell Therapy Annual Meeting, featuring oral and poster presentations. Key topics include advancements in gene therapy production and pivotal data from RGX-202 for Duchenne muscular dystrophy. The event emphasizes the company's leadership in gene therapy innovation.

Read more →

About REGENXBIO Inc.

Rockville, MD 371 employees regenxbio.com
Headquarters9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
BIOPHARMAWATCH ELITE
Trade the next RGNX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime